The use of sibutramine in the management of obesity and related disorders: An update

References

• JamesWPThe epidemiology of obesity: the size of the problemJ Intern Med2008263433635218312311
   PubMed Web of Science ®Google Scholar
• OgdenCLCarrollMDCurtinLRMcDowellMATabakCJFlegalKMPrevalence of overweight and obesity in the United States, 1999–2004JAMA2006295131549155516595758
   PubMed Web of Science ®Google Scholar
• TzotzasTKrassasGEPrevalence and trends of obesity in children and adults of South EuropePediatr Endocrinol Rev20041Suppl 344845416444173
   PubMedGoogle Scholar
• WilsonPWD’AgostinoRBSullivanLPariseHKannelWBOverweight and obesity as determinants of cardiovascular risk: the Framingham experienceArch Intern Med2002162161867187212196085
   PubMedGoogle Scholar
• YusufSHawkenSOunpuuSEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control studyLancet2004364943893795215364185
   PubMed Web of Science ®Google Scholar
• CalleEEThunMJPetrelliJMRodriguezCHeathCWJrBody-mass index and mortality in a prospective cohort of US adultsN Engl J Med1999341151097110510511607
   PubMed Web of Science ®Google Scholar
• FontaineKRReddenDTWangCWestfallAOAllisonDBYears of life lost due to obesityJAMA2003289218719312517229
   PubMed Web of Science ®Google Scholar
• PeetersABarendregtJJWillekensFMackenbachJPAl MamunABonneuxLObesity in adulthood and its consequences for life expectancy: a life-table analysisAnn Intern Med20031138243212513041
   PubMed Web of Science ®Google Scholar
• SnowVBarryPFittermanNQaseemAWeissKPharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of PhysiciansAnn Intern Med2005142752553115809464
   PubMed Web of Science ®Google Scholar
• BrayGAGreenwayFLPharmacological treatment of the overweight patientPharmacol Rev200759215118417540905
   PubMed Web of Science ®Google Scholar
• JonesDEnd of the line for cannabinoid receptor 1 as an anti-obesity target?Nat Rev Drug Discov200871296196219043439
   PubMed Web of Science ®Google Scholar
• FilippatosTDKiortsisDNLiberopoulosENMikhailidisDPElisafMSA review of the metabolic effects of sibutramineCurr Med Res Opin200521345746815811215
   PubMed Web of Science ®Google Scholar
• SharmaBHendersonDCSibutramine: current status as an anti-obesity drug and its future perspectivesExpert Opin Pharmacother20089122161217318671470
   PubMed Web of Science ®Google Scholar
• RollsBJShideDJThorwartMLUlbrechtJSSibutramine reduces food intake in non-dieting women with obesityObes Res1998611119526964
   PubMedGoogle Scholar
• BarkelingBElfhagKRoothPRossnerSShort-term effects of sibutramine (Reductil) on appetite and eating behaviour and the long-term therapeutic outcomeInt J Obes Relat Metab Disord200327669370012833113
   PubMed Web of Science ®Google Scholar
• HansenDLToubroSStockMJMacdonaldIAAstrupAThermogenic effects of sibutramine in humansAm J Clin Nutr1998686118011869846844
   PubMed Web of Science ®Google Scholar
• BerkowitzRIWaddenTATershakovecAMCronquistJLBehavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trialJAMA2003289141805181212684359
   PubMed Web of Science ®Google Scholar
• HansenDLToubroSStockMJMacdonaldIAAstrupAThe effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restrictionInt J Obes Relat Metab Disord199923101016102410557021
   PubMed Web of Science ®Google Scholar
• HainerVKunesovaMBellisleFHillMBraunerovaRWagenknechtMPsychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramineInt J Obes (Lond)200529220821615583700
   PubMed Web of Science ®Google Scholar
• Van MilEGWesterterpKRKesterADDelemarre-van de WaalHAGerverWJSarisWHThe effect of sibutramine on energy expenditure and body composition in obese adolescentsJ Clin Endocrinol Metab20079241409141417264187
   PubMed Web of Science ®Google Scholar
• WalshKMLeenELeanMEThe effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese femalesInt J Obes Relat Metab Disord199923101009101510557020
   PubMed Web of Science ®Google Scholar
• SeagleHMBessesenDHHillJOEffects of sibutramine on resting metabolic rate and weight loss in overweight womenObes Res1998621151219545017
   PubMedGoogle Scholar
• LevinBEDunn-MeynellAASibutramine alters the central mechanisms regulating the defended body weight in diet-induced obese ratsAm J Physiol Regul Integr Comp Physiol20002796R2222R222811080089
   PubMedGoogle Scholar
• BaranowskaBWolińska-WitortEMartyńskaLSibutramine therapy in obese women – effects on plasma neuropeptide Y (NPY), insulin, leptin and beta-endorphin concentrationsNeuro Endocrinol Lett200526667567916380708
   PubMedGoogle Scholar
• RodriguesAMRadominskiRBSuplicy HdeLDe AlmeidaSMNiclewiczPABoguszewskiCLThe cerebrospinal fluid/serum leptin ratio during pharmacological therapy for obesityJ Clin Endocrinol Metab20028741621162611932292
   PubMed Web of Science ®Google Scholar
• HanotinCThomasFJonesSPLeuteneggerEDrouinPEfficacy and tolerability of sibutramine in obese patients: a dose-ranging studyInt J Obes Relat Metab Disord199822132389481597
   PubMedGoogle Scholar
• SmithIGGoulderMARandomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesityJ Fam Pract200150650551211407998
   PubMed Web of Science ®Google Scholar
• BrayGABlackburnGLFergusonJMSibutramine produces dose-related weight lossObes Res19997218919810102256
   PubMedGoogle Scholar
• KimSHLeeYMJeeSHNamCMEffect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trialsObes Res20031191116112312972682
   PubMedGoogle Scholar
• KleinSBurkeLEBrayGAfor the American Heart Association Council on Nutrition, Physical Activity, and MetabolismClinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology FoundationCirculation2004110182952296715509809
   PubMed Web of Science ®Google Scholar
• DujovneCAZavoralJHRoweEMendelCMEffects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemiaAm Heart J2001142348949711526363
   PubMed Web of Science ®Google Scholar
• HaunerHMeierMWendlandGKurscheidTLauterbachKfor Study Group SA; SAT StudyWeight reduction by sibutramine in obese subjects in primary care medicine: the SAT StudyExp Clin Endocrinol Diabetes2004112420120715127325
   PubMed Web of Science ®Google Scholar
• PorterJARaebelMAConnerDAThe Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organizationAm J Manag Care200410636937615209480
   PubMedGoogle Scholar
• RuckerDPadwalRLiSKCurioniCLauDCLong term pharmacotherapy for obesity and overweight: updated meta-analysisBMJ200733576311194119918006966
   PubMed Web of Science ®Google Scholar
• Van GaalLFWautersMAPeifferFWDe LeeuwIHSibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction?Int J Obes Relat Metab Disord199822Suppl 1S38S409758242
   PubMedGoogle Scholar
• KamelEGMcNeillGVan WijkMCChange in intra-abdominal adipose tissue volume during weight loss in obese men and women: correlation between magnetic resonance imaging and anthropometric measurementsInt J Obes Relat Metab Disord200024560761310849583
   PubMed Web of Science ®Google Scholar
• JamesWPAstrupAFinerNEffect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and MaintenanceLancet200035692482119212511191537
   PubMed Web of Science ®Google Scholar
• ApfelbaumMVaguePZieglerOHanotinCThomasFLeuteneggerELong-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramineAm J Med1999106217918410230747
   PubMed Web of Science ®Google Scholar
• Mathus-VliegenEMLong-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group studyEur J Clin Nutr200559Suppl 1S31S3816052193
   PubMed Web of Science ®Google Scholar
• TurkMWYangKHravnakMSereikaSMEwingLJBurkeLERandomized clinical trials of weight loss maintenance: a reviewJ Cardiovasc Nurs2009241588019114803
   PubMed Web of Science ®Google Scholar
• WaddenTABerkowitzRISarwerDBPrus-WisniewskiRSteinbergCBenefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trialArch Intern Med2001161221822711176735
   PubMedGoogle Scholar
• WaddenTABerkowitzRIWombleLGRandomized trial of lifestyle modification and pharmacotherapy for obesityN Engl J Med2005353202111212016291981
   PubMed Web of Science ®Google Scholar
• PhelanSWaddenTABerkowitzRIImpact of weight loss on the metabolic syndromeInt J Obes (Lond)20073191442144817356528
   PubMed Web of Science ®Google Scholar
• WirthAKrauseJLong-term weight loss with sibutramine: a randomized controlled trialJAMA2001286111331133911560538
   PubMed Web of Science ®Google Scholar
• FinerNRyanDHRenzCLHewkinACPrediction of response to sibutramine therapy in obese non-diabetic and diabetic patientsDiabetes Obes Metab20068220621316448525
   PubMed Web of Science ®Google Scholar
• PadwalRSMajumdarSRDrug treatments for obesity: orlistat, sibutramine, and rimonabantLancet20073699555717717208644
   PubMed Web of Science ®Google Scholar
• DahlinABeermannBIncorrect use of orlistat and sibutramine in clinical practiceEur J Clin Pharmacol200763220520917205321
   PubMedGoogle Scholar
• HansenDAstrupAToubroSGoulder For The STORM Study Group MPredictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and MaintenanceInt J Obes Relat Metab Disord200125449650111319653
   PubMed Web of Science ®Google Scholar
• ElfhagKRossnerSBarkelingBRoothPSibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in moodPharmacol Res200551215916315629262
   PubMed Web of Science ®Google Scholar
• ElfhagKFinerNRossnerSWho will lose weight on sibutramine and orlistat? Psychological correlates for treatment successDiabetes Obes Metab200810649850517593239
   PubMed Web of Science ®Google Scholar
• PetersWRMacMurryJPWalkerJGieseRJJrComingsDEPhenylethanolamine N-methyltransferase G-148A genetic variant and weight loss in obese womenObes Res200311341541912634439
   PubMedGoogle Scholar
• HaunerHMeierMJockelKHFreyUHSiffertWPrediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphismPharmacogenetics200313845345912893983
   PubMedGoogle Scholar
• GrudellABSweetserSCamilleriMA controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adultsGastroenterology200813541142115418725220
   PubMed Web of Science ®Google Scholar
• WeinsteinARSessoHDLeeIMRelationship of physical activity vs body mass index with type 2 diabetes in womenJAMA2004292101188119415353531
   PubMed Web of Science ®Google Scholar
• KnowlerWCBarrett-ConnorEFowlerSEReduction in the incidence of type 2 diabetes with lifestyle intervention or metforminN Engl J Med2002346639340311832527
   PubMed Web of Science ®Google Scholar
• TuomilehtoJLindstromJErikssonJGPrevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose toleranceN Engl J Med2001344181343135011333990
   PubMed Web of Science ®Google Scholar
• GreggEWGerzoffRBThompsonTJWilliamsonDFTrying to lose weight, losing weight, and 9-year mortality in overweight US adults with diabetesDiabetes Care200427365766214988281
   PubMed Web of Science ®Google Scholar
• WilliamsonDFThompsonTJThunMFlandersDPamukEByersTIntentional weight loss and mortality among overweight individuals with diabetesDiabetes Care200023101499150411023143
   PubMed Web of Science ®Google Scholar
• FinerNBloomSRFrostGSBanksLMGriffithsJSibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled studyDiabetes Obes Metab20002210511211220522
   PubMed Web of Science ®Google Scholar
• Serrano-RiosMMelchiondaNMoreno-CarreteroERole of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapyDiabet Med200219211912411874427
   PubMedGoogle Scholar
• FujiokaKSeatonTBRoweEWeight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitusDiabetes Obes Metab20002317518711220553
   PubMed Web of Science ®Google Scholar
• McNultySJUrEWilliamsGA randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metforminDiabetes Care200326112513112502668
   PubMed Web of Science ®Google Scholar
• RedmonJBReckKPRaatzSKTwo-year outcome of a combination of weight loss therapies for type 2 diabetesDiabetes Care20052861311131515920044
   PubMedGoogle Scholar
• ArterburnDECranePKVeenstraDLThe efficacy and safety of sibutramine for weight loss: a systematic reviewArch Intern Med20041649994100315136309
   PubMedGoogle Scholar
• NorrisSLZhangXAvenellAEfficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysisArch Intern Med2004164131395140415249348
   PubMedGoogle Scholar
• MannucciEDicembriniIRotellaFRotellaCMOrlistat and sibutramine beyond weight lossNutr Metab Cardiovasc Dis200818534234817928208
   PubMedGoogle Scholar
• VettorRSerraRFabrisRPaganoCFederspilGEffect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studiesDiabetes Care200528494294915793204
   PubMed Web of Science ®Google Scholar
• DaskalopoulouSSAthyrosVGElisafMMikhailidisDPUric acid levels and vascular diseaseCurr Med Res Opin200420695195415200754
   PubMed Web of Science ®Google Scholar
• Pi-SunyerFXA review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesityClin Ther1996186100610359001821
   PubMed Web of Science ®Google Scholar
• KimDMYoonSJAhnCWSibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal womenDiabetes Res Clin Pract200466Suppl 1S139S14415563965
   PubMed Web of Science ®Google Scholar
• McLaughlinTAbbasiFLamendolaCKimHSReavenGMMetabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesityMetabolism200150781982411436188
   PubMedGoogle Scholar
• TambasciaMAGelonezeBRepettoEMGelonezeSRPicoloMMagroDOSibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trialDiabetes Obes Metab20035533834412940872
   PubMedGoogle Scholar
• ParekhSAnaniaFAAbnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver diseaseGastroenterology200713262191220717498512
   PubMed Web of Science ®Google Scholar
• SabuncuTNazligulYKaraoglanogluMUcarEKilicFBThe effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitisRom J Gastroenterol200312318919214502318
   PubMedGoogle Scholar
• RossRAtherosclerosis – an inflammatory diseaseN Engl J Med199934021151269887164
   PubMed Web of Science ®Google Scholar
• VisserMBouterLMMcQuillanGMWenerMHHarrisTBElevated C-reactive protein levels in overweight and obese adultsJAMA1999282222131213510591334
   PubMed Web of Science ®Google Scholar
• BastardJPJardelCBruckertEElevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight lossJ Clin Endocrinol Metab20008593338334210999830
   PubMed Web of Science ®Google Scholar
• FestaAD’AgostinoRJrHowardGMykkanenLTracyRPHaffnerSMChronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)Circulation20001021424710880413
   PubMed Web of Science ®Google Scholar
• HakAEStehouwerCDBotsMLAssociations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged womenArterioscler Thromb Vasc Biol19991981986199110446082
   PubMed Web of Science ®Google Scholar
• ShechterMBeigelRFreimarkDMatetzkySFeinbergMSShort-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery diseaseAm J Cardiol200697111650165316728231
   PubMedGoogle Scholar
• ValsamakisGMcTernanPGChettyRModest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokinesMetabolism200453443043415045687
   PubMed Web of Science ®Google Scholar
• HungYJChenYCPeiDSibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetesDiabet Med20052281024103016026368
   PubMedGoogle Scholar
• JungSHParkHSKimKSEffect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight lossJ Nutr Biochem200819637137517614271
   PubMed Web of Science ®Google Scholar
• AhimaRSOseiSYAdipokines in obesityFront Horm Res20083618219718230903
   PubMed Web of Science ®Google Scholar
• QuilliotDBohmePZannadFZieglerOSympathetic-leptin relationship in obesity: effect of weight lossMetabolism200857455556218328360
   PubMed Web of Science ®Google Scholar
• AbbasiFLamendolaCMcLaughlinTHaydenJReavenGMReavenPDPlasma adiponectin concentrations do not increase in association with moderate weight loss in insulin-resistant, obese womenMetabolism200453328028315015137
   PubMedGoogle Scholar
• FariaANRibeiro FilhoFFKohlmannNEGouvea FerreiraSRZanellaMTEffects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patientsDiabetes Obes Metab20057324625315811141
   PubMed Web of Science ®Google Scholar
• ArcaroGZamboniMRossiLBody fat distribution predicts the degree of endothelial dysfunction in uncomplicated obesityInt J Obes Relat Metab Disord199923993694210490799
   PubMedGoogle Scholar
• HashimotoMAkishitaMEtoMThe impairment of flow-mediated vasodilatation in obese men with visceral fat accumulationInt J Obes Relat Metab Disord19982254774849622346
   PubMedGoogle Scholar
• VakiliBAOkinPMDevereuxRBPrognostic implications of left ventricular hypertrophyAm Heart J2001141333434111231428
   PubMed Web of Science ®Google Scholar
• LevyDGarrisonRJSavageDDKannelWBCastelliWPPrognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart StudyN Engl J Med199032222156115662139921
   PubMed Web of Science ®Google Scholar
• VerdecchiaPAngeliFBorgioniCChanges in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysisAm J Hypertens20031611Pt 189589914573325
   PubMedGoogle Scholar
• de SimoneGDevereuxRBRomanMJAldermanMHLaraghJHRelation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adultsHypertension19942356006068175168
   PubMed Web of Science ®Google Scholar
• GottdienerJSRedaDJMatersonBJImportance of obesity, race and age to the cardiac structural and functional effects of hypertension. The Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive AgentsJ Am Coll Cardiol1994246149214987930281
   PubMed Web of Science ®Google Scholar
• WirthAScholzeJSharmaAMMatibaBBoennerGReduced left ventricular mass after treatment of obese patients with sibutramine: An echocardiographic multicentre studyDiabetes Obes Metab20068667468117026492
   PubMedGoogle Scholar
• ZannadFGilleBGrentzingerAEffects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reductionAm Heart J2002144350851512228789
   PubMed Web of Science ®Google Scholar
• MalhotraAWhiteDPObstructive sleep apnoeaLancet2002360932823724512133673
   PubMed Web of Science ®Google Scholar
• CaplesSMGamiASSomersVKObstructive sleep apneaAnn Intern Med2005142318719715684207
   PubMed Web of Science ®Google Scholar
• YeeBJPhillipsCLBanerjeeDCatersonIHednerJAGrunsteinRRThe effect of sibutramine-assisted weight loss in men with obstructive sleep apnoeaInt J Obes (Lond)200731116116816652122
   PubMed Web of Science ®Google Scholar
• MartinezDBasileBRSibutramine does not worsen sleep apnea syndrome: a randomized double-blind placebo-controlled studySleep Med20056546747016099715
   PubMedGoogle Scholar
• EhrmannDAPolycystic ovary syndromeN Engl J Med2005352121223123615788499
   PubMed Web of Science ®Google Scholar
• FlorakisDDiamanti-KandarakisEKatsikisIEffect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week studyInt J Obes (Lond)200832469269918071341
   PubMed Web of Science ®Google Scholar
• LindholmABixoMBjornIEffect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trialFertil Steril20088951221122817603048
   PubMed Web of Science ®Google Scholar
• SabuncuTHarmaMHarmaMNazligulYKilicFSibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndromeFertil Steril20038051199120414607575
   PubMedGoogle Scholar
• NewcomerJWAntipsychotic medications: metabolic and cardiovascular riskJ Clin Psychiatry200768Suppl 481317539694
   PubMed Web of Science ®Google Scholar
• HendersonDCCopelandPMDaleyTBA double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gainAm J Psychiatry2005162595496215863798
   PubMed Web of Science ®Google Scholar
• BaptistaTUzcateguiERangelNMetformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot studyPsychiatry Res20081591225025318295902
   PubMedGoogle Scholar
• HendersonDCFanXCopelandPMA double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gainActa Psychiatr Scand2007115210110517244173
   PubMed Web of Science ®Google Scholar
• Striegel-MooreRHFrankoDLShould binge eating disorder be included in the DSM-V? A critical review of the state of the evidenceAnnu Rev Clin Psychol2008430532418370619
   PubMed Web of Science ®Google Scholar
• AppolinarioJCGodoy-MatosAFontenelleLFAn open-label trial of sibutramine in obese patients with binge eating disorderJ Clin Psychiatry2002631283011838622
   PubMedGoogle Scholar
• AppolinarioJCBacaltchukJSichieriRA randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge eating disorderArch Gen Psychiatry200360111109111614609886
   PubMed Web of Science ®Google Scholar
• MilanoWPetrellaCCasellaACapassoACarrinoSMilanoLUse of sibutramine, an inhibitor of the reuptake of serotonin and noradrenaline, in the treatment of binge eating disorder: a placebo-controlled studyAdv Ther2005221253115943219
   PubMed Web of Science ®Google Scholar
• WilfleyDECrowSJHudsonJIEfficacy of sibutramine for the treatment of binge eating disorder: a randomized multicenter placebo-controlled double-blind studyAm J Psychiatry20081651515818056225
   PubMed Web of Science ®Google Scholar
• MersebachHKloseMSvendsenOLAstrupAFeldt-RasmussenUCombined dietary and pharmacological weight management in obese hypopituitary patientsObes Res200412111835184315601980
   PubMedGoogle Scholar
• MersebachHSvendsenOLAstrupAFeldt-RasmussenUAbnormal sympathoadrenal activity, but normal energy expenditure in hypopituitarismJ Clin Endocrinol Metab200388125689569514671154
   PubMedGoogle Scholar
• WangYLobsteinTWorldwide trends in childhood overweight and obesityInt J Pediatr Obes200611112517902211
   PubMed Web of Science ®Google Scholar
• OgdenCLCarrollMDFlegalKMHigh body mass index for age among US children and adolescents, 2003–2006JAMA2008299202401240518505949
   PubMed Web of Science ®Google Scholar
• TzotzasTKapantaisETziomalosKEpidemiological survey for the prevalence of overweight and abdominal obesity in Greek adolescentsObesity (Silver Spring)20081671718172218451778
   PubMedGoogle Scholar
• WangYMonteiroCPopkinBMTrends of obesity and underweight in older children and adolescents in the United States, Brazil, China, and RussiaAm J Clin Nutr200275697197712036801
   PubMed Web of Science ®Google Scholar
• FreedmanDSDietzWHSrinivasanSRBerensonGSThe relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart StudyPediatrics19991036 Pt 11175118210353925
   PubMed Web of Science ®Google Scholar
• DuncanGEPrevalence of diabetes and impaired fasting glucose levels among US adolescents: National Health and Nutrition Examination Survey, 1999–2002Arch Pediatr Adolesc Med2006160552352816651496
   PubMed Web of Science ®Google Scholar
• DanielsSRArnettDKEckelRHOverweight in children and adolescents: pathophysiology, consequences, prevention, and treatmentCirculation2005111151999201215837955
   PubMed Web of Science ®Google Scholar
• KrassasGETzotzasDDo obese children become obese adults: childhood predictors of adult diseasePediatr Endocrinol Rev20041Suppl 345545916444174
   PubMedGoogle Scholar
• GunnellDJFrankelSJNanchahalKPetersTJDavey SmithGChildhood obesity and adult cardiovascular mortality: a 57-y follow-up study based on the Boyd Orr cohortAm J Clin Nutr1998676111111189625081
   PubMed Web of Science ®Google Scholar
• EngelandABjorgeTSogaardAJTverdalABody mass index in adolescence in relation to total mortality: 32-year follow-up of 227,000 Norwegian boys and girlsAm J Epidemiol2003157651752312631541
   PubMed Web of Science ®Google Scholar
• BerkowitzRIFujiokaKDanielsSREffects of sibutramine treatment in obese adolescents: a randomized trialAnn Intern Med20061452819016847290
   PubMed Web of Science ®Google Scholar
• Godoy-MatosACarraroLVieiraATreatment of obese adolescents with sibutramine: a randomized, double-blind, controlled studyJ Clin Endocrinol Metab20059031460146515613431
   PubMed Web of Science ®Google Scholar
• McGovernLJohnsonJNPauloRTreatment of pediatric obesity. A systematic review and meta-analysis of randomized trialsJ Clin Endocrinol Metab200893124600460518782881
   PubMed Web of Science ®Google Scholar
• PinkneyJWildingJWilliamsGMacFarlaneIHypothalamic obesity in humans: what do we know and what can be done?Obes Rev200231273412119657
   PubMedGoogle Scholar
• TzotzasTPapazisisKPerrosPKrassasGEUse of somatostatin analogues in obesityDrugs200868141963197318778119
   PubMedGoogle Scholar
• DanielssonPJansonANorgrenSMarcusCImpact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromesJ Clin Endocrinol Metab200792114101410617726084
   PubMedGoogle Scholar
• BarlowSEExpert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary reportPediatrics2007120Suppl 4S164S19218055651
   PubMed Web of Science ®Google Scholar
• KayaAAydinNTopseverPEfficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patientsBiomed Pharmacother2004581058258715589067
   PubMedGoogle Scholar
• SariRBalciMKCakirMAltunbasHKarayalcinUComparison of efficacy of sibutramine or orlistat versus their combination in obese womenEndocr Res200430215916715473126
   PubMed Web of Science ®Google Scholar
• GokcelAGumurduluYKarakoseHEvaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesityDiabetes Obes Metab200241495511874442
   PubMed Web of Science ®Google Scholar
• EronduNAddyCLuKNPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramineObesity (Silver Spring)20071582027204217712121
   PubMedGoogle Scholar
• KiortsisDNTsouliSFilippatosTDKonitsiotisSElisafMSEffects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised studyNutr Metab Cardiovasc Dis200818320721017570651
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFMurdoloGEfficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patientsDiabetes Obes Metab200571475515642075
   PubMed Web of Science ®Google Scholar
• NeoviusMJohanssonKRossnerSHead-to-head studies evaluating efficacy of pharmaco-therapy for obesity: a systematic review and meta-analysisObes Rev20089542042718208467
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFMurdoloGCiccarelliLFogariRComparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patientsDiabetes Nutr Metab200417422222915575343
   PubMedGoogle Scholar
• WaddenTABerkowitzRIWombleLGSarwerDBArnoldMESteinbergCMEffects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trialObes Res20008643143711011909
   PubMedGoogle Scholar
• HuGBarengoNCTuomilehtoJLakkaTANissinenAJousilahtiPRelationship of physical activity and body mass index to the risk of hypertension: a prospective study in FinlandHypertension2004431253014656958
   PubMed Web of Science ®Google Scholar
• HuangZWillettWCMansonJEBody weight, weight change, and risk for hypertension in womenAnn Intern Med1998128281889441586
   PubMed Web of Science ®Google Scholar
• [No authors listed]Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research GroupArch Intern Med199715766576679080920
   PubMedGoogle Scholar
• StevensVJObarzanekECookNRfor the Hypertension Prevention Research GroupLong-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase IIAnn Intern Med2001134111111187414
   PubMed Web of Science ®Google Scholar
• JordanJScholzeJMatibaBWirthAHaunerHSharmaAMInfluence of Sibutramine on blood pressure: evidence from placebo-controlled trialsInt J Obes (Lond)200529550951615685250
   PubMed Web of Science ®Google Scholar
• HeusserKEngeliSTankJSympathetic vasomotor tone determines blood pressure response to long-term sibutramine treatmentJ Clin Endocrinol Metab20079241560156317284621
   PubMed Web of Science ®Google Scholar
• HeusserKTankJDiedrichAInfluence of sibutramine treatment on sympathetic vasomotor tone in obese subjectsClin Pharmacol Ther200679550050816678551
   PubMed Web of Science ®Google Scholar
• BirkenfeldALSchroederCBoschmannMParadoxical effect of sibutramine on autonomic cardiovascular regulationCirculation20021062459246512417543
   PubMed Web of Science ®Google Scholar
• McMahonFGFujiokaKSinghBNEfficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trialArch Intern Med2000160142185219110904462
   PubMed Web of Science ®Google Scholar
• McMahonFGWeinsteinSPRoweEErnstKRJohnsonFFujiokaKSibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitorsJ Hum Hypertens200216151111840224
   PubMed Web of Science ®Google Scholar
• SramekJJLeibowitzMTWeinsteinSPEfficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trialJ Hum Hypertens2002161131911840225
   PubMed Web of Science ®Google Scholar
• ScholzeJGrimmEHerrmannDUngerTKintscherUOptimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) studyCirculation2007115151991199817404163
   PubMed Web of Science ®Google Scholar
• HorvathKJeitlerKSieringULong-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysisArch Intern Med2008168657158018362248
   PubMedGoogle Scholar
• CookSTogniMSchaubMCWenaweserPHessOMHigh heart rate: a cardiovascular risk factor?Eur Heart J200627202387239317000632
   PubMed Web of Science ®Google Scholar
• GillumRFMakucDMFeldmanJJPulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up StudyAm Heart J19911211 Pt 11721771985358
   PubMed Web of Science ®Google Scholar
• ErnestDGershenzonACoralloCENagappanRSibutramine-associated QT interval prolongation and cardiac arrestAnn Pharmacother200842101514151718728104
   PubMedGoogle Scholar
• Harrison-WoolrychMClarkDWHillGRReesMISkinnerJRQT interval prolongation associated with sibutramine treatmentBr J Clin Pharmacol200661446446916542208
   PubMedGoogle Scholar
• PadwalRKezouhALevineMEtminanMLong-term persistence with orlistat and sibutramine in a population-based cohortInt J Obes (Lond)200731101567157017420781
   PubMed Web of Science ®Google Scholar
• PerrioMJWiltonLVShakirSAThe safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in EnglandObesity (Silver Spring)200715112712272218070762
   PubMed Web of Science ®Google Scholar
• HillGRAshtonJHarrison-WoolrychMSibutramine usage in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme. PharmacoepidemiolDrug Saf2007161112171226
   Google Scholar
• JamesWPThe SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patientsEur Heart J Supplements20057suppl LL44L48
   Google Scholar
• Torp-PedersenCCatersonICoutinhoWSCOUT InvestigatorsCardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trialEur Heart J200728232915292317595194
   PubMed Web of Science ®Google Scholar